These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 10235483)

  • 1. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
    Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm.
    Ragupathi G; Koganty RR; Qiu D; Lloyd KO; Livingston PO
    Glycoconj J; 1998 Mar; 15(3):217-21. PubMed ID: 9579798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
    MacLean GD; Reddish MA; Koganty RR; Longenecker BM
    J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Adv Exp Med Biol; 1994; 353():105-24. PubMed ID: 7527178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients.
    Adluri S; Helling F; Ogata S; Zhang S; Itzkowitz SH; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1995 Sep; 41(3):185-92. PubMed ID: 7553688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant.
    Longenecker BM; Reddish M; Koganty R; MacLean GD
    Ann N Y Acad Sci; 1993 Aug; 690():276-91. PubMed ID: 7690215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
    Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
    Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen.
    Zhang S; Walberg LA; Ogata S; Itzkowitz SH; Koganty RR; Reddish M; Gandhi SS; Longenecker BM; Lloyd KO; Livingston PO
    Cancer Res; 1995 Aug; 55(15):3364-8. PubMed ID: 7614472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn.
    O'Boyle KP; Zamore R; Adluri S; Cohen A; Kemeny N; Welt S; Lloyd KO; Oettgen HF; Old LJ; Livingston PO
    Cancer Res; 1992 Oct; 52(20):5663-7. PubMed ID: 1394190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.
    Miles D; Roché H; Martin M; Perren TJ; Cameron DA; Glaspy J; Dodwell D; Parker J; Mayordomo J; Tres A; Murray JL; Ibrahim NK;
    Oncologist; 2011; 16(8):1092-100. PubMed ID: 21572124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn.
    Kagan E; Ragupathi G; Yi SS; Reis CA; Gildersleeve J; Kahne D; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2005 May; 54(5):424-30. PubMed ID: 15625606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer.
    Miles DW; Towlson KE; Graham R; Reddish M; Longenecker BM; Taylor-Papadimitriou J; Rubens RD
    Br J Cancer; 1996 Oct; 74(8):1292-6. PubMed ID: 8883420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of antibody titers after immunization with monovalent or tetravalent KLH conjugate vaccines.
    Ragupathi G; Cappello S; Yi SS; Canter D; Spassova M; Bornmann WG; Danishefsky SJ; Livingston PO
    Vaccine; 2002 Jan; 20(7-8):1030-8. PubMed ID: 11803062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
    Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
    J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of the STn-KLH vaccine (Theratope).
    Ibrahim NK; Murray JL
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S139-43. PubMed ID: 12620151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-immunotherapy serum CA27.29 (MUC-1) mucin level and CD69+ lymphocytes correlate with effects of Theratope sialyl-Tn-KLH cancer vaccine in active specific immunotherapy.
    Reddish MA; MacLean GD; Poppema S; Berg A; Longenecker BM
    Cancer Immunol Immunother; 1996 Jun; 42(5):303-9. PubMed ID: 8706053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn.
    O'Boyle KP; Coatsworth S; Anthony G; Ramirez M; Greenwald E; Kaleya R; Steinberg JJ; Dutcher JP; Wiernik PH
    Cancer Immun; 2006 Mar; 6():5. PubMed ID: 16524255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes.
    Reddish MA; Jackson L; Koganty RR; Qiu D; Hong W; Longenecker BM
    Glycoconj J; 1997 Aug; 14(5):549-60. PubMed ID: 9298687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
    Miles D; Papazisis K
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S134-8. PubMed ID: 12620150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.